Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Evolent Health has nominated Richard Jelinek for election to its Board of Directors at the upcoming annual meeting scheduled for June 8, 2023. Jelinek, who is a managing partner at Czech One Capital Partners, has extensive experience in the health care sector, including executive roles at Aetna and CVS Health. His appointment coincides with the departure of current board member David Farner and former Chairman Frank Williams, both set to leave the board in June 2023. Evolent's leadership believes Jelinek's expertise will enhance the board's perspectives and support the company’s mission in value-based specialty care. The board expressed gratitude for the contributions of Farner and Williams, emphasizing the importance of evolving governance.
Summary not available.
Evolent Health (NYSE: EVH) announced on March 29, 2023, an agreement with Centene Corporation (NYSE: CNC) to enhance its Technology and Services solution for oncology care. This partnership will extend Evolent's oncology services to Centene’s Medicare Advantage members across the nation, deepening their existing collaboration in the specialty care market. Both companies aim to optimize oncology outcomes while managing costs effectively. Evolent's established platform, backed by scientific advisory boards, focuses on clinical quality and financial accountability, ensuring improved care delivery for patients.